



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/840,205	05/06/2004	Christopher E. Banas	6006-157	7254

7590 02/12/2007
ROSENBAUM & ASSOCIATES, P.C.
Suite #380
650 Dundee Road
Northbrook, IL 60062

EXAMINER

BARRETT, THOMAS C

ART UNIT	PAPER NUMBER
----------	--------------

3738

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	02/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/840,205	Applicant(s) BANAS ET AL.	
	Examiner Thomas C. Barrett	Art Unit 3738	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02 February 2007.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-16 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>2-07</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on February 2, 2007 has been entered.

Response to Arguments

Applicant's arguments with respect to claims 1-16 have been considered but are moot in view of the new ground(s) of rejection.

In regards to Van Schie et al, please note that Van Schie et al discloses:

To cause the curving as shown in FIGS. 4 and 6, a length of suture material 25 is fastened at 27 to the graft material or one of the stents and is then passed circumferentially around the prosthesis to a point 29 where it is inserted through the graft material and ***then extends longitudinally along the prosthesis*** to a point 30 where it is passed through a curve of one of the apices of the zig zag portions of the stent 21. (emphasis added).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-4 and 13-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Palmaz et al (WO 01/74274 A2). Palmaz et al discloses an implantable medical graft, comprising: a. a generally tubular body member comprising a film selected from the group consisting of metallic and pseudometallic materials (page 17, lines 1-7); and b. at least a portion of the body member having a plurality of undulations formed in walls of the body member by a support arranged in any manner as is known in the art of stent fabrication (page 5, lines 16-20), and microperforations (e.g. Figs. 2-3 and 8A-8C). However, Palmaz et al does not disclose the support arranged **specifically** as having continuous circumferential undulations. Palmaz et al also discloses (page 5, lines 13-25): "In accordance with one of the embodiments of the present invention, there is provided a stent-graft-type device, termed a "web-stent" in which there is at least one of a plurality of structural members that provide a primary means of structural support for the webbed-stent device. The plurality of structural members may be arranged in any manner as is known in the art of stent fabrication, e.g., single element **forming a circle or ellipse, a single or plural elements which form a tubular diamond-like or undulating pattern**, in which adjacent structural members are spaced apart forming open regions or interstices between adjacent structural members" (emphasis added). It would be obvious to one of ordinary skill in the art that the use of a plurality of single elements that each form a circle would result in a medical graft having continuous circumferential undulations.

Claims 5, 12 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Palmaz et al, in view of Van Schie et al (6,974,471 B2). Palmaz et al discloses an implantable medical graft as above. However, Palmaz et al does not disclose at least one suture member integrally extending along the longitudinal axis and through suture holes. Van Schie et al teaches an implantable medical graft comprising at least one suture member integrally extending along the longitudinal axis and through suture holes (e.g. Figs 4 and 6). It would have been obvious to one having ordinary skill in the art at the time the invention was made to combine the teaching of at least one suture member integrally extending along the longitudinal axis and through suture holes, as taught by Van Schie et al, to an implantable medical graft as per Palmaz et al, in order so that "the device can be curved insitu to fit the curved lumen" as found in Van Schie et al (col. 1, lines 44-52).

Claims 6-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Palmaz et al in view of Van Schie et al as above, and in further view of Kula et al (6,325,825 B1). Palmaz et al/ Van Schie discloses an implantable medical graft as above. However Palmaz et al/ Van Schie does not disclose the thickness of the undulating regions as less than that of the non-undulating regions. Kula et al teaches an implantable medical graft having thicker ends, which correspond to the non-undulating regions of Palmaz et al/ Van Schie (col. 4, lines 60-66). It would have been obvious to one having ordinary skill in the art at the time the invention was made to combine the teaching of an implantable medical graft having thicker ends, as taught by Kula et al, to an implantable medical graft as per Palmaz et al/ Van Schie, in order to "protect the

artery and any plaque from abrasion that may be caused by the stent 10 ends during insertion of the stent 10. The modification also may provide increased radio-opacity at the ends of the stent 10. Hence it may be possible to more accurately locate the stent 10 once it is in place in the body" as found in Kula et al (col. 4, lines 60-66).

Regarding claim 7 Palmaz et al/ Van Schie in further view of Kula et al fail to disclose the specific thicknesses of the claimed regions. However, Palmaz et al discloses that the thickness of the microperforated material is approximately 10 micrometers (page 21, lines 13-14). Palmaz et al also discloses that the undulations may be formed by a "subtractive" method (Fig. 10). The reduction of the undulation region relative to the non-undulated region would result in a thickness of the thinner region **about** 3-7 micrometers.

Furthermore, regarding claims 9-10, Palmaz et al/ Van Schie in further view of Kula et al fail to disclose the suturing openings as cruciform or generally Y-shaped slots. At the time the invention was made, it would have been obvious to a person of ordinary skill in the art to make the slots these shapes. Applicant has not disclosed that these shapes provides an advantage, is used for a particular purpose, or solve a stated problem. One of ordinary skill in the art, furthermore, would have expected Applicant's invention to perform equally well with either the holes of Van Schie et al or the claimed slots because both allow for the passage of sutures. Therefore, it would have been obvious to one of ordinary skill in the art to modify the cited references to obtain the invention as specified in claims 9 and 10. Please note that the Applicant may have intended to claim the microperforations as cruciform or generally Y-shaped slots.

Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Palmaz et al as above in view Banas et al (5,749,880). Palmaz et al discloses an implantable medical graft as above. However Palmaz et al does not disclose the implant having barbs. Banas et al teaches an implantable medical graft having projecting barb members (col. 14, lines 48-54). It would have been obvious to one having ordinary skill in the art at the time the invention was made to combine the teaching of projecting barb members, as taught by Banas et al, to an implantable medical graft as per Palmaz et al, in order to aid in anchoring to the target blood vessel wall, as in Banas et al (col. 14, lines 48-54).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas C. Barrett whose telephone number is (571) 272-4746. The examiner can normally be reached on Mon. -Fri. from 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Thomas C. Barrett
Examiner
Art Unit 3738

A handwritten signature in black ink, appearing to read "Tom Barrett", with a stylized flourish extending from the end.

TOM BARRETT
PRIMARY EXAMINER
TECHNOLOGY CENTER 3700